Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing transformative medicines for neurological diseases. The company's lead product candidate is LP352, which is in a Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. Its preclinical product candidates include LP659 and LP143, which focuses on developing therapies for multiple neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.

Longboard Pharmaceuticals, Inc.

Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Longboard is working to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). Longboard’s small molecule product candidates are based on more than 20 years of GPCR research. Longboard is evaluating LP352, an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with negligible observed impact on 5-HT2B and 5-HT2A receptor subtypes, in development for the potential treatment of seizures associated with a broad range of developmental and epileptic encephalopathies. Longboard is also evaluating LP659, a centrally acting, sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 modulator, in development for the potential treatment of multiple neurological diseases, and LP143, a centrally acting, full cannabinoid type 2 receptor (CB2) agonist, in development for the potential treatment of central nervous system (CNS) diseases and disorders.

	Dec '20	Dec '21	Dec '22	Dec '23
asset turnover
cash per share	3.27 -	7.41 126.50%	3.94 46.79%	2.13 45.85%
company equity multiplier	1.06 -	1.05 0.43%	1.15 8.94%	1.24 7.84%
days of inventory outstanding
days of payables outstanding				73.07K -
days of sales outstanding
dividend yield
ebit per revenue
ebt per ebit	1 -	1.00 0.15%	0.98 1.76%	0.96 2.26%
effective tax rate		0.00 -	0.02 743.06%
enterprise value multiple	-15.72 -	-0.16 98.97%	-1.02 533.35%	-2.17 111.94%
fixed asset turnover
free cash flow per share	-0.20 -	-1.72 743.14%	-2.22 29.37%	-2.24 0.86%
gross profit margin
interest coverage			-53.52 -
inventory turnover
long term debt to capitalization		0.00 -	0.01 245.55%
net income per ebt	1 -	1.00 0.23%	0.98 1.71%	1 1.98%
net profit margin
operating cash flow per share	-0.20 -	-1.71 742.59%	-2.22 29.45%	-2.24 0.86%
operating profit margin
payables turnover				0.00 -
pretax profit margin
price fair value	5.30 -	0.68 87.17%	0.91 33.64%	3.35 268.16%
receivables turnover
return on assets	-0.26 -	-0.25 0.59%	-0.61 139.74%	-1.07 75.91%
return on capital employed	-0.27 -	-0.27 0.82%	-0.72 169.29%	-1.39 91.50%
return on equity	-0.27 -	-0.27 1.02%	-0.70 161.18%	-1.33 89.70%
total debt to capitalization		0.01 -	0.01 135.74%	0.01 3.54%

COM:LONGBOARDPHARMA

Longboard Pharmaceuticals

Last Close

59.77

22/11 21:00

Market Cap

1.44B

Beta: -

Volume Today

1.29M

Avg: -

Preview